Research uncovers signaling pathways related to brain-immune system linksMay 16, 2006
New research on signaling pathways in immune cells bolsters evidence of connections between the central nervous system and the immune system. The findings may also advance the scientific foundation for a potential HIV treatment that may block the virus that causes AIDS.
The cell culture study by a research team from The Children's Hospital of Philadelphia and the University of Pennsylvania appears in the Proceedings of the National Academy of Sciences, published online on May 4.
The team, led by Steven D. Douglas, M.D., chief of the Section of Immunology at The Children's Hospital of Philadelphia, analyzed neurokinin-1 receptors found on the surfaces of monocytes, immune cells that develop into macrophages. The neurokinin-1 receptors (NK-1R) are docking sites for substance P, a well-known neurotransmitter that plays important roles in both immune function and the nervous system.
In the current study, the Douglas team investigated two forms of NK-1R in a human monocyte/macrophage cell line. One was a full-length receptor, the other a shortened version with fewer amino acids. When the researchers added substance P to cell cultures with the receptors, both responded with an increase in calcium ions, but used distinct signaling pathways.
The truncated NK-IR did not respond directly to substance P, but worked through another signaling molecule, the chemokine RANTES, to increase the calcium flow. The RANTES molecule is important because it binds to another cell receptor, CCR5, which is crucial in allowing common strains of HIV (R5 strains) to infect immune cells.
Significantly, when the investigators added the drug aprepitant, which binds to NK-1R, to their cell cultures, it inhibited signaling from both the full-length and short form of the receptors.
Although the current study was not focused on HIV infection, it directly relates to broader interests of Dr. Douglas' laboratory. He currently leads a four-year program project grant from the National Institute of Mental Health, entitled, "Neurokinin-1R (Substance P Receptor) Antagonists for HIV Therapy." One project within that grant will conduct a phase 1 (safety) trial of aprepitant in adults with HIV infection. Currently used as an anti-nausea medication, aprepitant, which has the trade name Emend, might also block HIV infection.
Because macrophages are a reservoir for HIV, a strategy that denies the virus entry into those immune cells may be important in combating HIV infection. Dr. Douglas showed in 2001 that another NK-1R antagonist blocked HIV replication within macrophages in cell culture. The hope is that aprepitant may show a similar protective effect in patients.
"We postulate that blocking NK-1R may send signals to turn off the CCR5 receptor for HIV, closing the door to the virus," said Dr. Douglas. "Underlying the signaling mechanisms are the questions, 'how does the immune system talk to the nervous system?' and 'how does the nervous system talk back?' Substance P is a link between both systems, and this study increases our understanding of those underlying questions."
Children's Hospital of Philadelphia
Related Immune Cells Current Events and Immune Cells News Articles
CWRU dental researchers find some immune cells change to prolong inflammation
Researchers at Case Western Reserve University School of Dental Medicine have unraveled one of the mysteries of how a small group of immune cells work: That some inflammation-fighting immune cells may actually convert into cells that trigger disease.
Discovery of a treatment to block the progression of multiple sclerosis
A drug that could halt the progression of multiple sclerosis may soon be developed thanks to a discovery by a team at the CHUM Research Centre and the University of Montreal.
Study discovers how pancreatic cancer spreads to the liver
An international team led by Weill Cornell Medical College investigators has illuminated the precise molecular steps that enable pancreatic cancer to spread to the liver -- the event that makes the most common form of the disease lethal.
Maternal obesity compromises babies' immune system at time of birth
Almost 60 percent of women of childbearing age in the United States are overweight or obese. Obesity is a major public health issue, and has been linked to health problems like heart disease, cancer and hypertension.
'Redesigned' antibodies may control HIV: Vanderbilt study
With the help of a computer program called "Rosetta," researchers at Vanderbilt University have "redesigned" an antibody that has increased potency and can neutralize more strains of the AIDS-causing human immunodeficiency virus (HIV) than can any known natural antibody.
Multiple sclerosis: Scientists ID cause of movement, balance problems
New research into the causes of the excessive inflammation that drives multiple sclerosis has identified a faulty "brake" within immune cells, a brake that should be controlling the inflammation.
Adults harbor lots of risky autoreactive immune cells, Stanford study finds
Decades' worth of textbook precepts about how our immune systems manage to avoid attacking our own tissues may be wrong.
Antiviral compound may protect brain from pathogens, West Nile virus study shows
Researchers have found that an antiviral compound may protect the brain from invading pathogens.
Novel insights in MET-proto-oncogene might lead to optimizing cancer treatment
The MET-proto-oncogene is involved in the pathogenesis of several tumors and therefore represents an interesting target for future therapies currently tested in dozens of clinical trials.
Men with asthma less likely to develop lethal prostate cancer
In what they are calling a surprising finding in a large study of men who completed questionnaires and allowed scientists to review their medical records, Johns Hopkins researchers report that men with a history of asthma were less likely than those without it to develop lethal prostate cancer.
More Immune Cells Current Events and Immune Cells News Articles